Advertisements
Feeds:
Posts
Comments

Search Results for 'PCSK9 '

Cholesterol Lowering Novel PCSK9 drugs: Praluent [Sanofi and Regeneron] vs Repatha [Amgen] – which drug cuts CV risks enough to make it cost-effective?

Posted in Atherogenic Processes & Pathology, Epigenetics and Cardiovascular Risks, Fatty acids, Frontiers in Cardiology and Cardiovascular Disorders, inflammation independent of lipid levels, Lipid metabolism, Lipidomics, Lipids, Origins of Cardiovascular Disease, PCSK9 Inhibitor Therapy, Pharmaceuticall R&D Informatics, Pharmacogenomics, Pharmacotherapy of Cardiovascular Disease, Systemic Inflammatory Diseases as CVD Risk, Value-based Drug Pricing on March 12, 2018| Leave a Comment »


 Cholesterol Lowering Novel PCSK9 drugs: Praluent [Sanofi and Regeneron] vs Repatha [Amgen] – which drug cuts CV risks enough to make it cost-effective? Reporter: Aviva Lev-Ari, PhD, RN   UPDATED on 1/15/2019 In the patent fight over PCSK9 inhibitors, the Supreme Court refused to hear Amgen’s appeal of a 2017 court decision allowing Sanofi and Regeneron […]

Read Full Post »

ODYSSEY Outcomes trial evaluating the effects of a PCSK9 inhibitor, alirocumab, on major cardiovascular events in patients with an acute coronary syndrome to be presented at the American College of Cardiology meeting on March 10.

Posted in Atherogenic Processes & Pathology, Frontiers in Cardiology and Cardiovascular Disorders, Heart Failure (HF), inflammation independent of lipid levels, Lipid metabolism, Lipidomics, Lipids, Origins of Cardiovascular Disease, PCSK9 Inhibitor Therapy, Pharmacotherapy of Cardiovascular Disease, tagged on February 28, 2018| Leave a Comment »


ODYSSEY Outcomes trial evaluating the effects of a PCSK9 inhibitor, alirocumab, on major cardiovascular events in patients with an acute coronary syndrome to be presented at the American College of Cardiology meeting on March 10. Reporter: Aviva Lev-Ari, PhD, RN   For PCSK9 inhibitors, the effect on major adverse cardiovascular events has always fallen short of expectations based on […]

Read Full Post »

FDA approval on 12/1/2017 of Amgen’s evolocumb (Repatha) a PCSK9 inhibitor for the prevention of heart attacks, strokes, and coronary revascularizations in patients with established cardiovascular disease

Posted in Atherogenic Processes & Pathology, Frontiers in Cardiology and Cardiovascular Disorders, Origins of Cardiovascular Disease, PCSK9 Inhibitor Therapy, Pharmacotherapy of Cardiovascular Disease on December 1, 2017| Leave a Comment »


FDA approval on 12/1/2017 of Amgen’s evolocumb (Repatha) a PCSK9 inhibitor for the prevention of heart attacks, strokes, and coronary revascularizations in patients with established cardiovascular disease Reporter: Aviva Lev-Ari, PhD, RN   Evolocumab was first FDA approved in 2015 for patients with familial hypercholesterolemia and others who fail to achieve LDL cholesterol lowering through diet and […]

Read Full Post »

Reversing Heart Disease: Combination of PCSK9 Inhibitors and Statins – Opinion by Steven Nissen, MD, Chairman of Cardiovascular Medicine at Cleveland Clinic

Posted in Atherogenic Processes & Pathology, Frontiers in Cardiology and Cardiovascular Disorders, Origins of Cardiovascular Disease, PCSK9 Inhibitor Therapy, Pharmacotherapy of Cardiovascular Disease, Vascular Diseases, tagged , , , , on December 29, 2016| Leave a Comment »


Reversing Heart Disease: Combination of PCSK9 Inhibitors and Statins – Opinion by Steven Nissen, MD, Chairman of Cardiovascular Medicine at Cleveland Clinic   Reporter: Aviva Lev-Ari, PhD, RN   UPDATED on 5/5/2017 Europeans Mull PCSK9i Post-FOURIER Fallout on Clinical Practice Patrice Wendling, May 04, 2017 But it was panelist Dr Stephen Nicholls (University of Adelaide, Australia) who […]

Read Full Post »

PCSK9 inhibitors: Reducing annual drug prices from more than $14 000 to $4536 would be necessary to meet a $100 000 per QALY threshold per JAMA

Posted in Atherogenic Processes & Pathology, Frontiers in Cardiology and Cardiovascular Disorders, Origins of Cardiovascular Disease, PCSK9 Inhibitor Therapy, tagged , on August 17, 2016| Leave a Comment »


PCSK9 inhibitors: Reducing annual drug prices from more than $14 000 to $4536 would be necessary to meet a $100 000 per QALY threshold per JAMA Curator: Aviva Lev-Ari, PhD, RN   UPDATED on 6/21/2017 When Cholesterol Drugs Cost $14,000, an Insurance Tug-of-War – PCSK9 inhibitors https://www.wsj.com/articles/when-cholesterol-drugs-cost-14-000-an-insurance-tug-of-war-1497889667   Our team has researched PCSK9 inhibitors as a class of drugs […]

Read Full Post »

Efficacy and Tolerability of PCSK9 Inhibitors by Patients with Muscle-related Statin Intolerance – New Cleveland Clinic study published in JAMA 4/2016

Posted in Atherogenic Processes & Pathology, Frontiers in Cardiology and Cardiovascular Disorders, Genetics & Innovations in Treatment, Genetics & Pharmaceutical, Genome Biology, HTN, Metabolomics, Origins of Cardiovascular Disease, PCSK9 Inhibitor Therapy, Pharmacotherapy of Cardiovascular Disease on April 3, 2016| Leave a Comment »


Efficacy and Tolerability of PCSK9 Inhibitors by Patients with Muscle-related Statin Intolerance – New Cleveland Clinic study published in JAMA 4/2016 Curators: Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN   Medical Interpretation of Study Results and the Pharmacological Treatment Context of PCSK9 Inhibitors Author: Larry H. Bernstein, MD, FCAP    The Rausse-3 Clinical […]

Read Full Post »

PCSK9: A Recent Discovery in Understanding Cholesterol Regulation @ AMGEN Cardiovascular

Posted in Atherogenic Processes & Pathology, Cardiovascular Research, Epigenetics and Cardiovascular Risks, Frontiers in Cardiology and Cardiovascular Disorders, Origins of Cardiovascular Disease, PCSK9 Inhibitor Therapy on August 4, 2015| Leave a Comment »


PCSK9: A Recent Discovery in Understanding Cholesterol Regulation @ AMGEN Cardiovascular Reporter: Aviva Lev-Ari, PhD, RN   UPDATED on 3/28/2016 ·       by Crystal Phend  Senior Associate Editor, MedPage Today Alirocumab (Praluent) reduced the frequency of apheresis by 75% compared with placebo and eliminated the need for apheresis for 63%, according to top-line results from the 62-patient phase […]

Read Full Post »

FDA ask Regeneron and Sanofi to assess potential Neurocognitive Side Effects of Alirocumab, PCSK9 inhibitors Class Designed to Block a Protein causing Persistence of “bad” LDL Cholesterol in the Bloodstream

Posted in Atherogenic Processes & Pathology, Biomarkers & Medical Diagnostics, Cardiovascular Pharmacogenomics, Chemical Biology and its relations to Metabolic Disease, Chemical Genetics, FDA Regulatory Affairs, Frontiers in Cardiology and Cardiovascular Disorders, Genome Biology, Origins of Cardiovascular Disease, PCSK9 Inhibitor Therapy, Pharmacotherapy of Cardiovascular Disease on March 7, 2014| Leave a Comment »


FDA ask Regeneron and Sanofi to assess potential Neurocognitive Side Effects of Alirocumab, PCSK9 inhibitors Class Designed to Block a Protein causing Persistence of “bad” LDL Cholesterol in the Bloodstream Reporter & Curator: Aviva Lev-Ari, PhD, RN UPDATED on 3/23/2016 PCSK9 inhibitor, Praluent, shows promise in late-stage study in reducing the frequency of apheresis therapy, […]

Read Full Post »

SNPs in apoE are found to influence statin response significantly. Less frequent variants in PCSK9 and smaller effect sizes in SNPs in HMGCR

Posted in Atherogenic Processes & Pathology, Biological Networks, Gene Regulation and Evolution, Biomarkers & Medical Diagnostics, Chemical Biology and its relations to Metabolic Disease, Chemical Genetics, Computational Biology/Systems and Bioinformatics, Frontiers in Cardiology and Cardiovascular Disorders, Genome Biology, Genomic Testing: Methodology for Diagnosis, Medical and Population Genetics, Origins of Cardiovascular Disease, PCSK9 Inhibitor Therapy, Personalized and Precision Medicine & Genomic Research, Pharmacogenomics, Pharmacotherapy of Cardiovascular Disease, Population Health Management, Genetics & Pharmaceutical on January 2, 2014| 4 Comments »


SNPs in apoE are found to influence statin response significantly. Less frequent variants in PCSK9 and smaller effect sizes in SNPs in HMGCR Reporter: Aviva Lev-Ari, PhD, RN Comprehensive Whole-Genome and Candidate Gene Analysis for Response to Statin Therapy in the Treating to New Targets (TNT) Cohort John F. Thompson, PhD, Craig L. Hyde, PhD, Linda S. […]

Read Full Post »

Two Mutations, in the PCSK9 Gene: Eliminates a Protein involved in Controlling LDL Cholesterol

Posted in Biomarkers & Medical Diagnostics, Chemical Biology and its relations to Metabolic Disease, Genome Biology, Genomic Testing: Methodology for Diagnosis, PCSK9 Inhibitor Therapy, Personalized and Precision Medicine & Genomic Research, tagged , , , , , , , , , on April 15, 2013| 4 Comments »


Two Mutations, in the PCSK9 Gene: Eliminates a Protein involved in Controlling LDL Cholesterol Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 11/15/2013 Relax, PCSK9ers: FDA won’t roadblock blockbusters from Sanofi, Amgen By Damian Garde On the heels of new guidelines casting doubts on a much-hyped new class of cholesterol drugs, the FDA said it would […]

Read Full Post »

Next »